Citations

Validation of a Care Pathway for the Use of Faecal Calprotectin in Monitoring Patients with Crohn’s Disease

BÜHLMANN fCAL® ELISA Citation: Turvill J, Rook L, Rawle M, et al. Validation of a care pathway for the use of faecal calprotectin in monitoring patients with Crohn's disease. Frontline Gastroenterology Published Online First: 30 January 2017. doi: 10.1136/flgastro-2016-100780. Highlights from this Publication “In patients with Crohn’s Disease, established on therapy, fecal calprotectin effectively identifies those who
Read more

Higher sensitivity detecting anti-myelin-associatedglycoprotein (MAG) IgM autoantibody using antigen purified from human brain

BÜHLMANN Anti-MAG Autoantibodies ELISA: Jaskowski et al. Higher sensitivity detecting anti-myelin-associatedglycoprotein (MAG) IgM autoantibody using antigen purified from human brain. 8th International Congress of Neuroimmunology. October 15-19, 2006.  Nagoya, Japan. Highlights from this Publication "The MAG EIA showed excellent sensitivity (97.5%) when compared to Western blot and has the advantages of being objective...and identifying [subjects] that
Read more

The Utility of Fecal Calprotectin in the Real-World Clinical Care of Patients with Inflammatory Bowel Disease

BÜHLMANN Quantum Blue® fCAL Citation: Abej, E. et al. The Utility of Fecal Calprotectin in the Real-World Clinical Care of Patients with Inflammatory BowelDisease Can J Gastroenterol Hepatol. 2016;2016:2483261. Epub 2016 Sep 28.DOI:10.1155/2016/2483261.  PMID: 27774443.  This Canadian study represents how FCAL testing is utilized in the field for monitoring disease activity in IBD.  The reference for the cut-off
Read more

Discovery of PI3K Delta Inhibitors for the Treatment of Inflammatory and Autoimmune Disease

Flow CAST® – Kinase Inhibtion Assay Citation: Matthews, D.J. et al. Discovery of PI3K delta inhibitors for the treatment of inflammatory and autoimmune disease. 2012 New York Academy of Sciences Meeting Poster.  "Importantly, PWT143 inhibits basophil activation (as measured by surface CD63 expression in a whole blood assay) with subnanomolar potency in response to anti-IgE stimulation
Read more